IGI Logo

Venus Remedies is currently trading at Rs. 200.75, up by 2.60 points or 1.31% from its previous closing of Rs. 198.15 on the BSE.

The scrip opened at Rs. 198.15 and has touched a high and low of Rs. 205.00 and Rs. 197.25 respectively. So far 3400 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 262.40 on 01-Jun-2022 and a 52 week low of Rs. 145.00 on 08-Feb-2023.

Last one week high and low of the scrip stood at Rs. 205.65 and Rs. 192.30 respectively. The current market cap of the company is Rs. 268.34 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.00% and 57.24% respectively.

Venus Remedies has secured a Good Manufacturing Practices (GMP) certification from Kenya for all its production facilities in Baddi. Acknowledging the commitment of Venus Remedies to quality assurance and international manufacturing standards, the Pharmacy and Poisons Board (PPB) of the Kenyan Health Ministry granted the certification following a rigorous audit of the company's production facilities in Baddi. With this, the number of international GMP certifications for Venus Remedies has gone up to 25. 

This recognition, a testament to Venus Remedies' commitment to delivering safe and effective drugs of the highest quality to patients worldwide, encompasses a wide range of parenteral formulations, including pre-filled syringes, ampoules, vial liquids and lyophilised and dry powder injections. Notably, the GMP certification extends to the manufacturing facilities for cephalosporins and carbapenems as dry powder injections, oral granules and liquid and lyophilised oncology products. 

The GMP from Kenya, estimated to be a $780 million market, is set to bolster the expansion of Venus Remedies in the COSMEA (Common Market for Eastern and Southern Africa) region, of which Kenya is a key member, and subsequently the entire African pharmaceutical market, which is estimated to be worth $7.3-billion. The company has a presence in Uganda, Tanzania, Kenya and Rwanda countries in Africa, where the pharmaceutical market is expected to grow upto $2.8 billion by year 2023 at a CAGR of around 10%. 

The GMP certification awarded by Kenya comes just three months after the company secured a GMP approval from Saudi Arabia, which is expected to speed up the process of marketing authorisations for the company's products in Gulf Cooperation Council (GCC) and Middle East and North Africa (MENA) regions.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.

JSW Steel rises on signing MoU with JFE Steel to establish CRGO electrical steel manufacturing JV in India